ArticleInternational journal of endocrinology and metabolism2019
Orbital Radiotherapy Plus Concomitant Steroids in Moderate-to-Severe Graves' Ophthalmopathy: Good Results After Long-Term Follow-Up.
Article in International journal of endocrinology and metabolism, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 21 citations in OpenAlex.
- Complications after radiotherapy in patients with Graves' orbitopathy: A nationwide cohort study.Eye (London, England) · 2026Article
- Early Low-Dose Rituximab for Mild-to-Moderate Thyroid Eye Disease: A Preliminary Evaluation of Efficacy and Safety.International journal of endocrinology · 2026Article
- No retinopathy after orbital irradiation in patients with thyroid eye disease - a follow up study.Frontiers in endocrinology · 2025Article
- Combining orbital intensity modulated radiation therapy with periorbital triamcinolone acetonide injection for Graves' orbitopathy.International journal of ophthalmology · 2025Article
- Review
- Stereotactic radiotherapy of radiation-induced meningioma previously irradiated retrobulbar for Graves' ophthalmopathy: A case report.Radiology case reports · 2024Article
- Advances in the Treatment of Thyroid Eye Disease Associated Extraocular Muscle Myopathy and Optic Neuropathy.Current neurology and neuroscience reports · 2022Review
- Is concomitant treatment with steroids and radiotherapy more favorable than sequential treatment in moderate-to-severe graves orbitopathy?La Radiologia medica · 2021Article
- Teprotumumab: a novel therapeutic monoclonal antibody for thyroid-associated ophthalmopathy.Expert opinion on investigational drugs · 2020Review
- Current Understanding of the Progression and Management of Thyroid Associated Orbitopathy: A Systematic Review.Ophthalmology and therapy · 2020Review
- Thyroid-associated ophthalmopathy: Emergence of teprotumumab as a promising medical therapy.Best practice & research. Clinical endocrinology & metabolism · 2020Review
- Improvement of the MRI and clinical features of Asian Graves' ophthalmopathy by radiation therapy with steroids.Japanese journal of radiology · 2019Article
- Thyroid Eye Disease: How A Novel Therapy May Change The Treatment Paradigm.Therapeutics and clinical risk management · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundOrbital radiotherapy (RT) is an effective and consolidate treatment for steroid-refractory Graves' ophthalmopathy (GO); however, long term effects are not well known.
objectivesThe aim of this study was to evaluate the long term efficacy and toxicity of orbital RT plus concomitant systemic steroids in a population of patients with moderate-to-severe GO or with eyesight threatening symptoms refractory to steroids.
methodsForty patients with moderate-to-severe GO or with eyesight threatening symptoms not responsive/resistant to steroids were treated with orbital RT at the dose of 20 Gy in 10 fractions plus concomitant steroids. Clinical activity score (CAS) and symptoms status were evaluated to determine response to the treatment.
resultsWe reported overall improvement of symptoms, in particular, a regression at 1-year of diplopia in 32.5% eye movement impairment in 42.5%, eyesight in 27.5% and a 2 point reduction in CAS. After a median time of 56 months 21.9% of the patients underwent orbital decompression for relapse of GO, 4.8% received surgical correction of strabismus, and 2.4% received eyelid lipectomy. Acute toxicity was mild; grade 1 - 2 keratitis occurred in 19.5% of the patients and grade 3 keratitis was observed in 2.4% of the patients. Cataract occurred in 7.4% of the patients after a median time of 24-month-follow-up. No secondary malignancies were reported.
conclusionsOur results reported the long-term efficacy and the good tolerance of orbital RT. The combination of RT plus steroids in this setting may avoid or delay performing the surgery in some cases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.